Norges Bank’s Revance Therapeutics, Inc. RVNC Stock Holding History

Norges Bank’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-161,000	Closed	-$489K	–	1888
2024 Q4	$489K	Hold	161,000	–	–	﹤0.01%	1795
2024 Q3	$836K	Hold	161,000	–	–	﹤0.01%	1747
2024 Q2	$414K	Hold	161,000	–	–	﹤0.01%	1891
2024 Q1	$792K	Hold	161,000	–	–	﹤0.01%	1813
2023 Q4	$1.42M	Hold	161,000	–	–	﹤0.01%	1828
2023 Q3	$1.85M	Hold	161,000	–	–	﹤0.01%	1842
2023 Q2	$4.07M	Hold	161,000	–	–	﹤0.01%	1767
2023 Q1	$5.19M	Hold	161,000	–	–	﹤0.01%	1741
2022 Q4	$2.97M	Buy	+161,000	New	+$3.68M	﹤0.01%	1911

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Norges Bank's RVNC Position: Q1 2025 in Review

Norges Bank sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 161,000 shares — an estimated $489K sold.

Norges Bank first reported a position in RVNC in Q4 2022 and held it in 9 quarters. The position peaked at $5.19M in Q1 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

Norges Bank reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
Norges Bank sold 161,000 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $489K.
Norges Bank first reported a position in Revance Therapeutics, Inc. in Q4 2022 and held it in 9 quarters.
Norges Bank's Revance Therapeutics, Inc. position peaked at $5.19M in Q1 2023.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Norges Bank's 13F filing for Q1 2025, filed 13 May 2025.